IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $178,398 | +84.1% | 4,647 | -9.0% | 0.11% | +89.5% |
| Q2 2023 | $96,880 | -6.8% | 5,107 | -23.8% | 0.06% | 0.0% |
| Q1 2023 | $103,933 | -36.9% | 6,701 | -27.8% | 0.06% | -33.7% |
| Q4 2022 | $164,649 | -2.6% | 9,276 | -69.5% | 0.09% | +28.4% |
| Q3 2022 | $169,000 | +43.2% | 30,367 | +0.7% | 0.07% | +52.3% |
| Q2 2022 | $118,000 | +0.9% | 30,146 | +42.5% | 0.04% | -15.4% |
| Q1 2022 | $117,000 | -38.7% | 21,162 | -5.7% | 0.05% | -27.8% |
| Q4 2021 | $191,000 | +11.0% | 22,435 | +13.3% | 0.07% | -5.3% |
| Q3 2021 | $172,000 | -21.8% | 19,794 | -5.0% | 0.08% | -15.6% |
| Q2 2021 | $220,000 | +122.2% | 20,827 | +239.0% | 0.09% | +114.3% |
| Q1 2021 | $99,000 | -64.4% | 6,143 | +1.9% | 0.04% | -63.5% |
| Q4 2020 | $278,000 | – | 6,028 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |